Search

A recent report from the Royal Children's Hospital in Victoria, Australia, discusses the use of chimeric antigen receptor (CAR) T cell therapy in childhood leukemia, specifically targeting the CD19 antigen. This therapy has shown success in treating relapsed B-cell acute lymphoblastic leukemia (B-ALL) when other treatments have failed. The report highlights real-world considerations for clinicians, such as manufacturing time, administration, patient care, toxicities, and outcomes, as well as the uncertainty surrounding when to use CAR T cell therapy in conjunction with hematopoietic stem cell transplant. The research has been peer-reviewed and provides valuable insights into this innovative treatment approach for pediatric leukemia. [Extracted from the article]

Researchers from the Fred Hutchinson Cancer Research Center conducted a Phase I clinical trial to investigate the safety and efficacy of CD19 CAR T-cell therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The study involved 23 patients who received JCAR021 infusion, resulting in an overall response rate of 82% and a complete response rate of 64%. Durable remissions were observed in patients with low marrow disease burden, highlighting the need for new strategies to prolong remissions. The study concluded that similar outcomes were observed in patients receiving CD19 CAR T-cells with fully human or murine scFv-containing CAR. [Extracted from the article]

A recent study conducted at Children's Hospital Philadelphia focused on the outcomes of cell therapy in pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who experienced extramedullary relapse after CD19 CAR T-cell therapy. The research aimed to describe the incidence, patterns, salvage strategies, and long-term outcomes of post-CAR19 extramedullary relapses. The study found that outcomes after extramedullary relapse were generally poor, highlighting the need for further research and improved treatment strategies in this patient population. [Extracted from the article]

A recent study from the University College London (UCL) Great Ormond Street Institute of Child Health discusses the challenges of relapse after CD19-directed CAR T-cell therapy in B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL). The study explores the use of dual-targeting CAR T cells that target CD19 and an additional antigen, such as CD22 or CD20, to address this issue. The research highlights the need for further advancements in CAR T-cell therapy to overcome antigen-positive relapses and improve treatment outcomes for patients with these conditions. [Extracted from the article]

Researchers at Kyoto Prefectural University of Medicine have conducted a study on immunoglobulins, focusing on enhancing the anti-leukemic functionality of CD19 CAR-T cells through selective JAK2 pathway inhibition. The study explores the synergistic effect of combining a selective type II JAK2 inhibitor, CHZ868, with CD19 CAR-T cells, leading to improved anti-leukemic activity across B-cell tumor models. The research suggests that the selective inhibition of the JAK2 pathway may enhance CAR-T cell therapy and provide a potential treatment option for patients with resistant B-cell leukemias. [Extracted from the article]

Research data from the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany, has provided new insights into gene therapy, specifically focusing on non-viral vectors for chimeric antigen receptor immunotherapy. The study highlights the potential of non-viral vectors, such as mRNA and precision genome editors, as cost-effective and scalable alternatives for CAR T cell therapy. The research discusses advancements in gene delivery methods, clinical outcomes, and considerations for translating these technologies into practice, emphasizing the promise of non-viral vectors in optimizing cell-based treatments. [Extracted from the article]

The article discusses the use of bivalent aptamer assemblies targeting B-cell markers CD19 and CD20 in the diagnosis and treatment of B-cell-related malignancies and autoimmune diseases. Through Ligand-Guided Selection (LIGS), researchers synthesized dimeric constructs of aptamers with polyethylene glycol linkers, demonstrating enhanced binding affinity and specificity. The study suggests that bivalent aptamers could be developed into cost-effective and precise therapeutic agents for conditions like diffuse large B-cell lymphoma. The research highlights the potential of aptamer-based synthetic therapeutics in clinical applications. [Extracted from the article]

A recent study from Tianjin First Central Hospital explores the impact of IL4I1 on the efficacy of CD19 CAR-T therapy combined with PD-1 inhibitors in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The research suggests that IL4I1 expression may hinder the effectiveness of this combination therapy by enhancing immunosuppression through the IDO-AHR-Kyn pathway. By targeting IL4I1, there may be potential for improving treatment outcomes for DLBCL patients. The study highlights the importance of understanding the role of IL4I1 in enhancing immunosuppression and its implications for combination therapy in DLBCL treatment. [Extracted from the article]

A recent study from the University of Utah examined the use of tafasitamab followed by CD19-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. The study found that patients who received tafasitamab before CAR-T therapy showed varying responses, with some achieving complete or partial responses. The research highlights the importance of understanding disease response and CD19 expression in patients undergoing sequential anti-CD19 therapies for B-cell lymphoma. [Extracted from the article]

A study conducted by researchers at Shanghai Jiao Tong University School of Medicine focused on B-cell non-Hodgkin lymphoma (B-NHL) and the use of CD19 Chimeric antigen receptor T (CAR T) cell immunotherapy. The research found that low doses of chidamide increased the functionality of CD19 CAR T cells in killing B-NHL cells and enhancing cytokine secretion. In vivo experiments showed that chidamide intervention improved the therapeutic effect of CD19 CAR T cells in B-NHL, providing a new direction for therapy. The study was published in Discover Oncology and can be accessed for free online. [Extracted from the article]

Researchers at Baylor College of Medicine conducted a study on the impact of CD3z ITAM multiplicity and sequence on CAR T-cell survival and function. They found that manipulating CD3z ITAM sequences in CAR T-cells can alter signaling strength, with zAAA CARs showing stronger signaling compared to zBBB and zCCC CARs. The study suggests that weaker signaling zCCC CARs may be better candidates for improving the long-term survival and persistence of CAR T-cells in patients. This research was supported by the National Cancer Institute and published in Frontiers in Immunology. [Extracted from the article]

Researchers at Shanghai Jiao Tong University School of Medicine conducted a study on the impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL. The study found that the rational use of corticosteroids did not affect the clinical efficacy, overall survival, or persistence of CAR-T cells in patients with B-ALL. The researchers concluded that while corticosteroids did not impact the therapy's effectiveness, further clinical or experimental verification is needed to determine the dosage threshold. [Extracted from the article]

A study conducted by the Russian Academy of Sciences explored the adjuvant effect of benzo(a)pyrene (BaP) on specific IgE production and B-cell subpopulations in a mouse allergy model. The research found that BaP significantly stimulated the production of allergen-specific IgG1 and IgE, as well as increased the content of certain B-cell subpopulations in the spleen and lung tissue. The study concluded that BaP's adjuvant effect on IgE production was associated with the stimulation of germinal centers in the spleen and extrafollicular activation of B-cells in lung tissue. [Extracted from the article]

A study conducted at Peking University People's Hospital in Beijing, China, focused on the impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy. The research evaluated 116 children with R/R B-ALL who received this therapy, with a high complete response rate of 98.3% and overall survival and event-free survival rates of 69.3% and 59.0%, respectively. The study found that pre-infusion disease burden is a predictor of long-term outcomes in pediatric patients receiving anti-CD19 CAR T-cell therapy for R/R B-ALL. [Extracted from the article]

The article discusses the development of a comprehensive T cell perturbation genomics database, TCPGdb, to identify critical T cell regulators for enhancing T cell anti-tumor capability and persistence in the tumor microenvironment. The database integrates data from various genetic screens and gene expression analyses to provide a systematic and robust analysis of gene perturbations on T cell function. Users can access TCPGdb through a webserver to explore the impact of query genes on T cell function based on prior screen data and a T cell screen perturbation score (TPS) module. The preprint has not been peer-reviewed and aims to revolutionize T cell-based immunotherapies. [Extracted from the article]

Researchers at Kocaeli University have conducted new research on T-cell lymphoma, focusing on the use of CAR-T cell therapy to treat various lymphoma subtypes. The study highlights the effectiveness of CD19-targeted CAR-T therapies in B-cell lymphomas and explores innovative delivery strategies to enhance treatment outcomes. The research also discusses the challenges and advancements in using CAR-T cell therapy for T-cell lymphomas, including targeting less common antigens and localized delivery methods for CNS lymphomas. Overall, CAR-T cell therapy shows promise in transforming the treatment landscape for lymphomas, offering new hope to patients with previously untreatable forms of the disease. [Extracted from the article]

Researchers at Marmara University have detailed data on monoclonal antibodies, focusing on their role in immunotherapy for acute lymphoblastic leukemia (ALL). Various immunotherapies, such as bispecific antibodies, antibody-drug conjugates, CAR T-cell, and CAR NK cell therapies, are being studied as alternative treatment regimens to target cancer cells using the patient's immune system. The study highlights the efficacy and side effects of different monoclonal antibodies, such as blinatumomab and inotuzumab, in treating ALL, emphasizing the ongoing research into optimal combinations and integration stages into therapy. [Extracted from the article]

Researchers from Huazhong University of Science and Technology conducted a study on the impact of type I interferon on CAR-T cell therapy. They found that type I interferon impairs the function of CAR-T cells by disrupting immune synapse assembly, leading to reduced cytotoxicity and weaker anti-tumor effects in preclinical models. The study suggests that editing IFNAR1 in CAR-T cells could enhance their potency and resistance to the immunosuppressive effects of type I interferon. This research provides new insights into potential strategies to improve CAR-T cell therapy efficacy. [Extracted from the article]

Researchers from Zhejiang University School of Medicine conducted a retrospective study on the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with relapsed/refractory B-ALL. The study included 23 participants with a median age of 58.1 years, and key endpoints focused on minimal residual disease-negative complete remission, overall survival, and leukemia-free survival. The research concluded that sequential CD19 and CD22 CAR-T cell therapy shows durable efficacy and a manageable safety profile in addressing antigen-loss relapse in patients ineligible for allo-HSCT, offering a promising treatment option for improving long-term outcomes. [Extracted from the article]

Researchers at Huazhong University of Science and Technology in Wuhan, China, have developed a novel IL-12 delivery system using extracellular vesicles (EVs) modified with the target antigen CD19 to enhance the functionality of CAR-T cells in cancer therapy. The study demonstrated that IL-12 EVs significantly improved the effector function of CAR-T cells in vitro and resulted in durable anti-tumor responses in a mouse model of lymphoma xenograft without causing systemic toxicity. This research suggests that CAR target-modified EVs could serve as an effective and safe adjuvant in combination therapy with CAR-T cells, offering a promising approach to improve cancer treatment outcomes. [Extracted from the article]

A recent report from the Medical University of Warsaw discusses research findings on acute lymphoblastic leukemia, focusing on the response rates to first-line salvage treatments after anti-CD19 CAR-T cell therapy failure in adult patients. The study conducted a meta-analysis of various salvage interventions, including retreatment with anti-CD19 and anti-CD22 CAR-T cells, blinatumomab, inotuzumab ozogamicin, and allogeneic stem cell transplantation. Results showed a pooled complete remission rate of 43% for anti-CD19 CAR-T cells and 78% for anti-CD22 CAR-T cells, highlighting the importance of reporting and analyzing management strategies after CAR-T cell therapy failure in B-ALL patients. The study emphasizes the need for further research due to data scarcity and the complex factors influencing treatment decisions in these cases. [Extracted from the article]

A recent study conducted by researchers at the University of Miami focused on B-cell lymphoma and the resistance mechanisms to CD19 CAR T-cell therapy in aggressive large B-cell lymphoma (LBCL) patients. The study analyzed genomic complexity and identified new genomic drivers involved in CAR19 resistance, particularly in immune-synapse and CD19 pathways. The findings suggest that genomic instability plays a crucial role in treatment resistance by affecting the relationship between CAR19 cell activity, the immune system, and tumor cell immunogenicity. This research provides valuable insights into the mechanisms underlying therapy resistance in LBCL patients. [Extracted from the article]

A study conducted at University Hospital Tubingen in Germany focused on the long-term immunological consequences of CD19 CAR T cell therapy in patients with Diffuse Large B Cell Lymphoma. The research found that while bacterial infections were common in the first 30 days post-infusion, viral infections became more prevalent later on. The study highlighted deficiencies in CD4+ T cells, CD19+ B cells, and immunoglobulin levels at 6 and 12 months after treatment, emphasizing the need for further research to optimize prophylactic approaches for long-term infections in this patient population. [Extracted from the article]

Researchers at Nanfang Hospital of Southern Medical University in Guangzhou, China, conducted a study to evaluate the effectiveness of low-dose Decitabine in combination with autologous hematopoietic stem cell infusion for patients experiencing persistent pancytopenia after CD19-chimeric antigen receptor T (CAR-T) therapy. The study involved two adult patients with relapsed DLBCL and ongoing pancytopenia following CD19-CART therapy. Both patients achieved hematopoietic reconstitution following treatment with low-dose Decitabine and autologous hematopoietic stem cell infusion, indicating a potential therapeutic option for addressing bone marrow failure. Further research is needed to determine the efficacy and safety of this combined approach. [Extracted from the article]

A recent study from Memorial Sloan-Kettering Cancer Center explores the development of induced pluripotent stem cell-derived T cells that exhibit similar characteristics to primary CAR T cells. The research highlights the potential of using iPSC-derived T cells as an off-the-shelf approach to cell therapy, addressing challenges in generating uniform drug products for patients. The study emphasizes the functional, phenotypic, and transcriptomic similarities between CD8ab+ iT cells and primary T cells, showcasing promising outcomes for cancer treatment. This research offers valuable insights into the potential of iPSC technology in advancing cell therapy options. [Extracted from the article]

A recent study conducted at the University Hospital Tubingen in Germany explored the use of dual CD19/CD22-targeting CAR-T cells in patients with Richter's transformation (RT) of chronic lymphocytic leukemia (CLL) to diffuse large B cell lymphoma (DLBCL). The research focused on two patients who experienced successful long-term complete remission after treatment with academically manufactured CAR-T cells. The study highlighted the potential of dual-targeting CAR-T therapy in aggressive RT cases, emphasizing the need for new therapies to improve outcomes for patients with CLL. The findings suggest promising results for further clinical trials to validate the efficacy and safety of this approach in RT patients. [Extracted from the article]

The article discusses a follow-up study, NCT06721598, evaluating the safety and efficacy of anti-CD19 CAR-T cell therapy in adults with relapsed or refractory B-cell lymphoproliferative disorders. The study aims to assess the long-term outcomes of CAR-T therapy, focusing on patient tolerance, cancer remission, and treatment effectiveness. Participants who previously received CAR-T therapy will undergo regular follow-up visits over approximately 11 months to monitor side effects and track CAR-T cell activity. The study, conducted in Russia, aims to provide insights into improving outcomes for patients with B-cell malignancies. [Extracted from the article]

Researchers at Amsterdam University Medical Center have conducted a Phase 1 clinical trial using CD22-directed CAR T-cells (CAR22) to treat patients with mantle cell lymphoma (MCL) and follicular lymphoma (FL) who had relapsed after CD19-directed CAR T-cell therapy. The trial showed promising results with an overall response rate (ORR) of 68% and a complete remission (CR) rate of 53%. The therapy was well tolerated with no significant toxicity reported, and further research is ongoing to evaluate its effectiveness in other types of lymphoma. [Extracted from the article]

A recent study conducted at Memorial Sloan-Kettering Cancer Center focused on the treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory Mantle Cell Lymphoma (MCL). The study found that patients with progression of disease post-CAR-T therapy had a poor prognosis, with a median overall survival of 5.4 months. The presence of a TP53 mutation significantly predicted inferior overall survival, highlighting the importance of this finding in the post-CAR-T context. The study also showed promise for bispecific antibodies, with an overall response rate of 60%. [Extracted from the article]

A recent study from Duke University focused on the molecular and clinical determinants of CAR-T therapy response in patients with Diffuse Large B-cell Lymphoma (DLBCL). The study highlighted the challenges and limitations of CAR-T therapy, including its efficacy, cost, and side effects. By analyzing genomic features of tumors before treatment, researchers identified predictors of patient outcomes, which could potentially lead to the development of precision medicine approaches using CAR-T therapy for DLBCL. The study emphasized the importance of identifying patients likely to respond to therapy to improve outcomes in this challenging disease. [Extracted from the article]

A recent study discussed in Immunotherapy Weekly focuses on the safety and efficacy of FT522, a novel iPSC-derived CD19 CAR NK cell therapy for B-cell lymphoma. The therapy aims to reduce the need for conditioning chemotherapy while maintaining anti-tumor activity. Initial results show that FT522 was well-tolerated, with some patients achieving complete responses, and ongoing dose escalation is being conducted. The study highlights the potential of FT522 in treating relapsed/refractory B-cell lymphomas, with promising outcomes observed in the first cohort studied. [Extracted from the article]

A study conducted at Children's Hospital Los Angeles compared the performance of enhanced flow cytometry (MFC) and Next Generation Sequencing (NGS) in detecting low levels of measurable residual disease (MRD) in B lymphoblastic leukemia (B-ALL). The research found that both MFC and NGS were effective in identifying MRD, with some cases showing discordant results due to changes in clonal sequences post-therapy. The study suggests that MFC and NGS are complementary and provide valuable insights into the biology and clinical outcomes of B-ALL. For more information, the full article can be accessed for free at https://doi.org/10.1182/blood-2024-212324. [Extracted from the article]

A recent study conducted at Weill Cornell Medicine Cornell University focused on the response to CAR-T therapy in patients with relapsed or refractory Mantle Cell Lymphoma (MCL). The research aimed to identify biomarkers that could predict outcomes and resistance mechanisms in this setting. The study included 88 patients from 5 international centers and found that traditional molecular features associated with poor outcomes in MCL did not significantly impact response or survival in patients treated with CD19-CAR-T therapy. The findings suggest the potential utility of CAR-T therapy even in patients with high-risk MCL features, emphasizing the need for novel biomarkers to predict treatment success. [Extracted from the article]

A recent study conducted by a researcher at PSL University in Paris, France, has revealed that FAS ablation can confer resistance to allogeneic CAR-T rejection by T cells in the absence of NK cell sensitization. Allogeneic CAR-T cells derived from healthy donors show promise in overcoming limitations associated with autologous cancer therapies, providing standardized and affordable batches with improved efficacy. The study suggests that CD3-FAS double-KO allogeneic CAR-T cells may offer partial protection from both T and NK cell-mediated allo-rejection, potentially enhancing the efficacy of cellular therapies for patients with B-cell neoplasms and cancer in general. [Extracted from the article]

A recent study conducted at Sungkyunkwan University explored the impact of co-treatment with anti-CD19 monoclonal antibody on the antitumor activity of anti-CD19 CAR-T and -NK cells. The research found that this co-treatment enhanced the serial killing activity of these cells and reduced trogocytosis, ultimately leading to improved therapeutic efficacy against B cell malignancies. The study highlighted the temporal modulation effects of the antibody on the antitumor activity of the CAR-T cells, emphasizing the potential benefits of combining antibody therapy with cell-based treatments. [Extracted from the article]

A recent study conducted at the University of Pennsylvania focused on improving treatment outcomes for mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). Researchers explored the use of CDK9 inhibitors in combination with CD19 CAR-T therapy to overcome therapy resistance and enhance treatment efficacy. The study found that this combinatorial approach showed promise in addressing resistance mechanisms and improving patient outcomes, with potential applications across various B-cell malignancies. The findings suggest a promising avenue for advancing lymphoma therapy and potentially impacting patient care in the future. [Extracted from the article]

A research study conducted by Huazhong University of Science and Technology in Wuhan, China, focused on the impact of immunogenicity of humanized anti-CD19 CAR-T cells on the efficacy and prognosis of B-cell malignancies. The study developed a quantitative detection method for anti-drug antibody (ADA) levels and found that high levels of ADA were associated with poor CAR-T cell expansion and prognosis. The research suggests that monitoring ADA levels in plasma could serve as a biomarker for guiding clinical strategies and enhancing personalized diagnostics and treatments in the future. [Extracted from the article]

A study conducted by Zhejiang University focused on the long-term efficacy and safety of CD19-specific CAR-T cells armed with IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. The study followed 39 patients for up to 5 years, with a median age of 55 years and various disease characteristics. Results showed a median overall survival of 31 months, with a 5-year overall survival rate of 43.6% among all patients and 64.6% among those achieving complete remission. The study concluded that the armored CAR-T cells demonstrated continued benefit for patients with relapsed or refractory large B-cell lymphoma, paving the way for future clinical research. [Extracted from the article]

Researchers at the University of Alberta have made significant advancements in understanding immunologic receptors, particularly in the context of anti-CD19 CAR T-cell therapy for aggressive B-cell cancers. By analyzing gene expression profiles of enriched T-cells before and after CAR T-cell manufacturing, they found that certain genes and pathways were associated with treatment response. This research may help identify patients who are more likely to benefit from CAR T-cell therapy in future clinical trials. The study was published in Blood and conducted by a team led by Michael P. Chu at the Cross Cancer Institute in Edmonton, Canada. [Extracted from the article]

Researchers at the Institute of Hematology and Blood Diseases Hospital have conducted a study on CD19 chimeric antigen receptor (CAR) T-cell therapy for refractory autoimmune hemolytic anemia (rAIHA). The study involved patients who had failed multiple therapies and received CD19 CAR T-cell infusions, showing promising results with a 100% complete remission rate. The therapy induced rapid remission, sustained drug-free remission, and had a favorable safety profile, suggesting that CAR T-cell therapy could be a novel strategy for treating autoimmune hemolytic anemia. The research supports further clinical trials in this area. [Extracted from the article]

A recent study conducted at the H. Lee Moffitt Cancer Center in Tampa, Florida, focused on the incidence and severity of cytopenias associated with CD19-targeted CAR-T cell therapy. The study included 26 randomized control trials and 38 observational studies, revealing that cytopenias, such as neutropenia, thrombocytopenia, anemia, and lymphopenia, are common among patients undergoing this therapy. The findings underscore the importance of recognizing and managing these cytopenias to improve patient outcomes. The study was conducted following rigorous methodology and adhered to preferred reporting guidelines for systemic reviews and meta-analyses. [Extracted from the article]

A new study conducted at Stanford University School of Medicine explores the use of allogeneic CD19/CD22-CAR T cells in combination with myeloablative graft-engineered allo-HCT for high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study aims to enhance graft versus leukemia without increasing acute graft-versus-host disease (GVHD) or graft failure. Initial results show promising outcomes, with all patients achieving minimal residual disease-negative complete remission without severe toxicities. This research suggests a potential new treatment approach for patients with high-risk B-ALL and other hematologic diseases. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Soochow University in Suzhou, China, focused on evaluating the efficacy and safety of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in relapsed t(8;21) acute myeloid leukemia (AML) patients. The study included ten patients who received CD19 CAR-T cells after lymphodepletion chemotherapy, showing a high safety profile and efficacy with a 100% response rate. While the therapy demonstrated promising results, relapse, mainly characterized by CD19-negative phenotypes, was common within six months post-treatment. The research suggests that CD19 CAR-T therapy could be a potential new strategy for disease remission with manageable side effects, emphasizing the importance of maintenance therapy for long-term outcomes. [Extracted from the article]

Researchers at Tongji Hospital of Tongji University in Shanghai, China, conducted a clinical evaluation of a non-viral, 2-day rapid manufacture CAR T-cell therapy for B-cell malignancies. The study included four patients with relapsed or refractory B-cell malignancies, showing promising results with manageable side effects such as cytokine release syndrome. The research suggests that this therapy may offer a favorable safety profile and encouraging efficacy for patients with heavily pretreated B-cell malignancies, warranting further investigation through phase 1 studies. [Extracted from the article]

A recent study conducted at the University of Tokyo focused on evaluating the immune functionality of CAR T-cells using molecular imaging flow cytometry (MI-FCM) to analyze the change in CAR molecule localization. The researchers genetically modified peripheral blood mononuclear cells from healthy donors to express an anti-CD19 CAR and evaluated the cytotoxic activity of these clones in vitro. The study found that quantifying the superficial CAR T-cell concentration using MI-FCM could be a valuable method for assessing their immune function and antitumor response. [Extracted from the article]

A recent study conducted at Universitat Autonoma de Barcelona analyzed the clinical outcomes of patients with relapsed/refractory B-cell acute lymphoblastic leukemia receiving autologous chimeric antigen receptor (CAR) T-cell therapy. The meta-analysis included 1,154 patients from 30 trials and found that CAR T-cell therapy showed promising efficacy and manageable toxicity. The study highlighted that products using 4-1BB as the costimulatory domain had better efficacy and safety outcomes compared to those using CD28, and CD22-CAR had a better toxicity profile but lower efficacy than CD19-CAR. [Extracted from the article]

A recent study conducted by researchers at Huazhong University of Science and Technology in China explored the synergistic effects of combining BTK inhibitors with CD19-targeted CAR-T cells in patients with relapsed or refractory B-cell lymphoma. The study involved an open-label clinical trial with 37 patients, where the combination therapy showed promising results in terms of response depth and long-term survival. The researchers concluded that prolonging the duration of BTK inhibitor maintenance could lead to improved immune function and better outcomes for patients with B-cell lymphoma. The study was published in the journal Blood and can be accessed for free online. [Extracted from the article]

Researchers at Huazhong University of Science and Technology conducted a study on the combination effects of Selinexor (SEL) and CD19 CAR-T cells in B-cell lymphoma (BCL). The study found that patients with lower XPO-1 expression had longer overall and progression-free survival. SEL improved CAR-T cell functionality and reduced immunosuppression of macrophages, making the sequential administration of SEL and CAR-T cells more effective in treating BCL. The findings were published in Blood, and more information can be found in the journal article. [Extracted from the article]

Researchers at the University of Colorado Anschutz Medical Campus have conducted a study on acute lymphoblastic leukemia (B-ALL) and its resistance to conventional chemotherapy. The research focused on the role of TP53 mutations in compromising the effectiveness of CD19-directed CAR-T cell therapy for relapsed B-ALL. They found that inhibiting free fatty acid transport, specifically targeting the FATP2 transporter, could potentially improve CAR-T therapy outcomes for B-ALL patients. This study sheds light on a potential metabolic vulnerability in B-ALL that could enhance the efficacy of CAR-T cell therapy. [Extracted from the article]

A recent study conducted at the Second Affiliated Hospital of Anhui Medical University in China focused on B-cell lymphoma and the challenges of resistance and relapse in CD19 Chimeric antigen receptor (CAR) T-cell therapy. The research highlighted the role of therapy-induced senescence (TIS) in tumor resistance and identified CCR7 as a key factor in promoting senescence in aggressive B-NHL cells. Inhibiting CCR7 was found to enhance the killing ability of CD19 CAR-T cells against B-cell lymphoma cells by suppressing senescence and stemness characteristics. [Extracted from the article]